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a  b  s  t  r  a  c  t
Invasive  Group-B  streptococcal  (GBS)  disease  is  a leading  cause  of  infant  mortality  and morbidity  world-
wide.  GBS  colonises  the maternal  rectum  and vagina  and  transmission  of  bacteria  from  a colonized  mother
to her  infant  at birth  is  an  important  risk  factor for GBS  disease.  GBS  disease  has  also  been  associated
with  case  reports  of  transmission  via  infected  breast  milk  raising  questions  about  mode  of acquisition  and
transmission  of  this  enteric  pathogen  and  the  development  of  neonatal  disease.  However,  most  breast-
fed  infants  remain  unaffected  by  GBS  in  breast  milk.  Mechanisms  associated  with  transmission  of  GBS
in  breast  milk  and  potential  factors  that  may  protect  the  infant  from  transmission  remain  poorly  under-
stood.  Understanding  factors  involved  in protection  or transmission  of  GBS  infection  via breast  milk  is
important  both  for premature  infants  who  are  a high-risk  group  and  for infants  in the  developing  world
where  breastfeeding  is the  only  sustainable  infant  feeding  option.  In this  review  we discuss  the  proposed
mechanisms  for  GBS  colonization  in breast  milk on  one  hand  and its  immune  factors  that  may  protect
from  transmission  of  GBS  from  mother  to infant  on  the  other.  Innate  and  adaptive  immune  factors,  includ-
ing  serotype-speciﬁc  antibody  and  their signiﬁcance  in the  prevention  of infant  disease  are  presented.  We
further  report  on  the  role of  human  oligosaccharides  in  protection  from  invasive  GBS  disease.  Advances
in  our  knowledge  about  breast  milk  and  immunity  in GBS  disease  are  needed  to  fully  appreciate  what
might  mitigate  transmission  from  mother  to  infant  and  protect  neonates  from  this  devastating  disease
and  to contribute  to the  development  of novel  prevention  strategies,  including  maternal  immunization
to  prevent  infant  disease.
ublis©  2014  The  Authors.  P
. Introduction
Streptococcus agalactiae (Lanceﬁeld Group B streptococcus; GBS)
as ﬁrst described as a cause of bovine mastitis by Nocard and
ollereau in 1887 [1]. Lanceﬁeld and Hare subsequently identiﬁed
BS in vaginal swabs in 1935 [2] and in 1938 Fry described three
atal cases in post-partum women [3]. Reports of neonatal disease
rom GBS were sporadic until the early 1960s when GBS became
ecognized as a leading cause of early neonatal sepsis in the USA
4]. By the 1970s it had become the dominant pathogen in the early
eonatal period [5]. By the early 1980s GBS had become the most
ommon cause of neonatal sepsis and meningitis in a number of
eveloped countries [6–8]. In the past ﬁve years, late-onset (LO)
BS disease has been associated with case reports of transmission
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via infected breast milk [9] raising questions about mode of acquisi-
tion and transmission of this enteric pathogen and the development
of neonatal disease.
Although GBS is not just a neonatal disease, the disease inci-
dence and severity is highest during the ﬁrst 90 days of life. Early
onset (EO) GBS disease (disease presenting in the ﬁrst six days of
life) accounts for approximately 60–70% of all GBS disease. GBS
serotypes Ia, Ib, II, III and V are responsible for most EO disease
[10,11]. In contrast, serotype III predominates in LO disease, which
may be acquired perinatally, nosocomially or from the community.
[12]
In the USA EO disease rates have declined from 1.4 per 1000
live births in 1990 [13] to at 0.28 per 1000 live births in 2012 [14]
mainly attributed to the implementation of universal screening for
GBS rectovaginal colonization in pregnant women and intrapartum
antibiotic prophylaxis. However, the incidence of LO disease has
remained static at between 0.3 and 0.4 per 1000 births since 1990
[14]. This amounts to 28,100 cases and 1865 deaths annually in
the USA [14]. Although the epidemiology of GBS in resource-rich
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ountries is well documented, its contribution to the burden of
eonatal infection in low/middle income countries has proved
ore difﬁcult to assess. GBS has been reported as the predomi-
ant cause of neonatal sepsis in South Africa and Kenya [15–17]
s well as an important cause of meningitis in Malawi and Kenya,
ut Asian studies have reported a much lower incidence [18–20].
 recent systematic review reported that the overall incidence of
BS in resource-poor settings ranged between 0 and 3.06 per 1000
ive births [21].
GBS colonizes the rectum and vagina, and maternal colonization
s a pre-requisite for EO disease and a risk factor for LO [22,23]. In
esource-rich countries an estimated 20–30% of pregnant women
re colonized with GBS [23,24], approximately 50% of their babies
ecome colonized and 1% progress to develop invasive disease. EO
isease may  occur rapidly; signs of sepsis are evident at birth or
ithin 12 h in over 90% of cases (98% within the ﬁrst 12 h) [12].
espite its rarity, LO disease, mostly presenting as meningitis, has
evastating long term consequences in survivors with up to 50%
uffering severe neurological sequelae [25].
It has been suggested that GBS initially colonizes the infant’s
ropharyngeal mucosa when contact with maternal vaginal secre-
ions occur at the time of birth [26]. Butter and DeMoor
emonstrated GBS in the nose and throat of infants at the same time
s GBS was cultured from the mother’s breast milk [27]. Fileron et al.
eviewed cases of LOGBS disease associated with GBS in breast milk
nd found 48 LOGBS disease cases between January 1977 and March
013 of which four had no other positive culture from mother or
nfant other than GBS-contaminated breast milk. [9].
Therefore, there appears to be a dichotomy between cases of
O disease through infected breast milk and the potential bene-
ts of the components of breast milk which protect the majority of
nfants from invasive disease. The underlying mechanisms of GBS
ransmission or protection through breast milk, are not fully under-
tood, but are important to elucidate, particularly in the context
f premature infants who are a high risk group and for infants in
he developing world where breastfeeding is the only sustainable
nfant feeding option. In this review we focus on the peculiarities
f GBS that may  aid transmission in breast milk and the role of
mmune parameters such as antibody in breast milk on the other
and that may  help protect the breastfed infant from GBS disease.
. Breast milk as vector of transmission of GBS
.1. GBS in breast milk
Few studies have identiﬁed presence of GBS in breast milk, and
ethodological differences make comparisons difﬁcult [28–32].
ow incidence is described in mothers of extremely preterm infants
f 0.4% [31] and term infants of 0.82%. Higher incidence in raw milk
anged from 3.5% [30] to 10% [29] in donor breast milk. However,
he concurrent incidence of GBS colonization in these mothers and
he effect of intrapartum and postpartum antibiotic treatment were
nknown.
The variety of delivery, treatment and storage methods of breast
ilk offers potential for GBS contamination. Human breast milk
ay  contain 103 to 109 cfu/mL of GBS at any point, representing a
eservoir of potential infection for the neonatal gut [33]. Breast milk
irectly from the mother (either through natural breast feeding or
s expressed breast milk) is given raw and is rarely cultured in cases
f neonatal infection. Expressed breast milk and bank milk may
e frozen, which affects immune components and bank milk may
lso be pasteurized. Pasteurization is thought to eradicate impor-
ant viral and bacterial infections [34] but also depletes milk of the
ajority of its cellular components and immunoglobulins [35] and
ay  increase the bacterial growth rate [36].ine 32 (2014) 3128–3132 3129
Very recently, best practices on the use of breast milk in the
context of prevention of GBS neonatal disease have been proposed,
including the search for GBS in milk at the time of recurrent GBS
neonatal disease and in cases of mastitis in mothers of high-risk
preterm neonates admitted to neonatal intensive care units [37].
For these neonates, microbiological control of raw milk has also
been proposed in the absence of mastitis [37]. However, the best
strategy has yet to be developed as it does not appear that pasteur-
izing maternal milk changes the overall incidence of late onset GBS
disease in preterm infants [38]. In a recent review article of cases
of late onset GBS disease from breast milk, GBS was  found in 0–2%
of raw milk samples and 1.4% of pasteurized milk samples [9].
2.2. Proposed methods of acquisition
Two  main mechanisms of acquisition have been proposed: fol-
lowing colonization of the neonatal oropharynx at the time of
birth, mothers may  develop colonization of the milk ducts through
ascending infection from the neonate, due to the retrograde ﬂow
of milk associated with suckling. The infant is then reinfected as
the concentration of bacteria increases in the breast milk [39]. This
may  occur with or without mastitis depending on additional fac-
tors such as milk stasis and bacterial load [40]. In most of the case
reports of GBS disease associated with breast milk there is no sign
of maternal mastitis, indicating silent maternal duct colonization
[9]. However, recent studies in animal models and discovery of
lactobacilli in breast milk after oral administration suggest that
bacteria from the maternal digestive tract may also colonize the
breast. [41] It has also been suggested that lactic acid bacteria may
transfer from the mother’s gut to breast milk and through the milk
to the infant’s digestive tract [42]. The epidemiological relationship
between neonatal and maternal derived GBS isolates in breast milk
has been conﬁrmed by polymerase chain reaction (PCR) [43]. How-
ever, it is not clear whether the LO disease relates to infected breast
milk or is a result of gut translocation from an already colonized
infant.
GBS may  infect the submucosa of the gastrointestinal tract
either through a defect in the epithelial cell layer, or by concomitant
infectious agents [33]. As neonatal gastric acid secretion is reduced,
more bacteria may  reach the intestinal mucosa. This is supported
by ﬁndings that preterm infants fed with contaminated maternal
milk via nasogastric tube have developed GBS disease [44].
3. Breast milk as vehicle of protection from GBS infection
3.1. Innate and adaptive immune properties of breast milk
Breast milk is the main source of non-pathogenic bacteria to the
infant gastrointestinal tract. Intestinal bacteria are one of the most
important stimuli for the development of mucosa-associated lym-
phoid tissue (MALT) in the neonatal small intestine [45] and pro-
duce organic acids that prevent growth of enteric pathogens. Addi-
tionally, breast milk and colostrum contain many components with
antimicrobial and immunomodulatory properties that are believed
to impair translocation of infectious pathogens [46]. Some of these
substances compensate directly for deﬁciencies in the neonatal
immune system and enhance survival of defense agents, including
secretory IgA (SIgA), lactoferrin, lysozyme, IFN-; some adapt the
gastrointestinal tract to extrauterine life, i.e. epidermal growth fac-
tor [47]; some prevent inﬂammation or enhance speciﬁc-antibody
production, such as PAF-acetylhydrolase, antioxidants, interleukins
1, 6, 8, and 10, transforming growth factor (TGF), secretory leuko-
cyte protease inhibitors (SLPI), and defensin 1 [46]. Breast milk also
contains substantial amounts of intracellular adhesion molecule
1 and vascular adhesion molecule 1; low quantities of soluble
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-selectin, l-selectin and CD14, which may  mediate differentia-
ion and growth of B cells [46]. Natural autoantibodies, thought to
e important in the selection of the pre-immune B cell repertoire
nd in the development of immune tolerance, are also detected in
olostrum and in breast milk [48]. Recently, the beneﬁcial effects of
uman oligosaccharides in prevention of neonatal diarrhoeal and
espiratory tract infections have been highlighted [49,50].
Human breast milk is known to contain factors that can modu-
ate toll-like receptor (TLR) signaling, including soluble TLR2, which
an competitively inhibit signaling through membrane TLR2 [51],
s well as a protein that inhibits TLR2-mediated and activates TLR4-
ediated transcriptional responses in human intestinal epithelial
nd mononuclear cells by an as-yet-unknown mechanism [52]. It
as been speculated that reduced TLR2 responsiveness at birth may
acilitate the normal establishment of beneﬁcial Gram-positive biﬁ-
obacteria intestinal ﬂora. Lipids present in human milk have been
hown to inactivate GBS in vitro, providing additional beneﬁt to
rotect from invasive infection at the mucosal surfaces [53].
. Antibody in breast milk
Neonates have low levels of SIgA and SIgM [54] thus protection
rom invasive pathogens at the mucosal surface relies on antibod-
es in breast milk. As antibody in breast milk is produced following
ntigenic stimulation of the maternal MALT and bronchial tree
bronchomammary pathway) [55], these antibodies are targeted
o many infectious agents encountered by the mother both prior to
irth and during the breastfeeding period.
It is currently hypothesized that SIgA represents the crucial
rimary protective component of breast milk [56,57]. SIgA pro-
ects against mucosal pathogens by immobilizing these, preventing
heir adherence to epithelial surfaces, or by neutralizing toxins
r virulence factors. SIgA concentration is far higher in colostrum
12 mg/ml) than in that found in mature milk (1 mg/ml). A breastfed
nfant may  ingest around 0.5–1.0 g of SIgA per day [40].
. The role of SIgA in breast milk
SIgA production is enhanced by Interleukin-6 (IL-6) whilst the
roduction of secretory components is enhanced by TNF- and
GF- causes class switching towards B cells producing IgA [47],
ll of which are present in breast milk.
SIgA antibodies present in breast milk are speciﬁc for numerous
nteric and respiratory pathogens. In studies from resource-poor
ountries, breast milk-mediated protection against infections with
ibrio cholerae, Campylobacter,  Shigella, Giardia lamblia and respira-
ory tract infections was signiﬁcantly related to the content of SIgA
ntibody in breast milk against these pathogens [58–60]. This could
upport the hypothesis that similar protection could be obtained
rom SIgA antibody in breast milk to GBS in a highly breastfed
opulation. However, maternal SIgA does not appear to enter the
eonatal circulation, [61] except in preterm infants, where inges-
ion of milk rich in IgA to respiratory syncytial virus (RSV) resulted
n increased serum IgA levels during the perinatal period [62], so
ts effectiveness is limited to the mucosal surface.
SIgA is more resistant to proteolysis than other immunoglobu-
ins and is therefore able to function in the gastrointestinal tract
46]. This could account for the ﬁnding that the faeces of breast fed
nfants contains IgA by the second day of life, compared to 30% of
ormula-fed infants, where IgA is only found in faeces by one month
f age [63].
Breast milk contains SIgA antibodies against bacterial-adhesion-
ite-like pili [46,64]. SIgA antibody in milk blocks adherence of S.
neumoniae and Haemophilus inﬂuenza to human retropharyngealine 32 (2014) 3128–3132
cells [64] and casein in vitro [65]. The neutralizing capacity of milk
anti-poliovirus antibodies has also been reported [66,67].
The effect of third trimester maternal immunization with a sin-
gle dose of licensed quadrivalent meningococcal vaccine on the
potential protection of infants, including by breast milk demon-
strated elevated N. meningitidis-speciﬁc IgA antibodies in breast
milk up to six months post partum in vaccinated infants [68].
Similarly, in mothers who received pneumococcal polysaccharide
vaccine (PSV) during the third trimester, the geometric mean con-
centration of IgA in breast milk was signiﬁcantly higher two months
postpartum than in women  who received conjugate H. inﬂuenzae
vaccine in the third trimester and remained higher at seven months
post partum. [69]
6. Group B Streptococcal antibody in breast milk
As described above, high levels of breast milk SIgA could
offer protection to neonates via interference of antibody with
the carbohydrate-mediated attachment of GBS to nasopharyngeal
epithelial cells. Through this mechanism, colonizing organism load
may  be reduced with a consequent reduction in morbidity and
mortality caused by GBS in the neonatal period [70].
In transition milk, low or moderate IgA antibodies to CPS type III
GBS, were detected in approximately 63% of a cohort of 70 Swedish
women [71]. In a study of IgG antibody concentration in transition
milk in 46 women  from the USA, Weisman and Dobson [70] found
concentrations of IgG to types Ia, II or III which were approximately
10% of those in maternal serum. Edwards et al. measured IgG and
IgA in breast milk to type III GBS in 18 women with high and low
antibody titers and found measurable levels of antibody in both
groups up to 2 months post-delivery [72]. Detectable levels of CPS
serotype III antibody in breast milk in women  correlated with con-
currently high levels in their serum. Whilst no studies demonstrate
a correlation between GBS-antibody levels in breast milk and infant
colonization, Berardi et al. report that GBS-positive breast milk is
associated with heavy infant colonization [73].
To determine the effect of maternal immunization with GBS
CPS-II and CPS-III antibody on postnatal protection from disease
a rodent model has been used, where increased survival in pups
exposed postnatally to breast milk with high titers of antibody
compared to low titers was  shown, supporting the beneﬁcial added
effect of breast milk antibody following vaccination [74,75].
7. Human oligosaccharides
Oligosaccharides prevent cell adherence for S. pneumoniae [76]
and Escherichia coli (E. coli) [77]. Additionally, E. coli and Campy-
lobacter jejuni toxin can be neutralized by oligosaccharides [49,78]
and milk glycoconjugates prevent cell adherence of Vibrio cholera
and E. coli [79,80]. Taken together, these studies suggest that the
transfer of human milk oligosaccharides delivers real protection to
infants against many bacterial and viral infections.
GBS type Ib and II polysaccharides are of interest as they are vir-
tually identical to certain oligosaccharides present in human milk
[75,81,82] which raises the possibility of cross-reactivity with other
human glycoconjugates [83]. The results from murine models sug-
gest that these oligosaccharides may  act as receptor analogues that
anchor the bacteria in the mucosal layer and prevent cell adhesion
in the epithelial layer, thus preventing invasive disease.
8. ConclusionMost neonatal infections occur via mucosal membranes in
the respiratory, gastrointestinal, and urinary tracts, yet there is
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eonatal period. Breast milk provides considerable amounts of
peciﬁc SIgA antibodies that are produced as a result of microbial
nd food antigens the mother has previously encountered. Such
IgA antibodies from breast milk provide protection to the neonate
t the mucosal surface. Breast milk additionally contains high
oncentrations of non-speciﬁc protective molecules, such as lacto-
errin that has bactericidal, viricidal, and fungicidal properties.
ilk oligosaccharides might block adherence of microorganism at
he mucosal surface by functioning as receptor analogues.
There is increasing data from recent publications that enhanced
rotection against diarrhea, respiratory tract infections, otitis
edia and H. inﬂuenzae infections, as well as wheezing illness
ay  persist for years after breastfeeding. However, the role
f breast milk antibody in protection from neonatal GBS dis-
ase remains poorly understood. Current research is evaluating
ransport, persistence and function of GBS antibodies and other
mmune-constituents in breast milk. These studies aim to identify
rotective factors involved in the passive transfer of immune com-
onents in breast milk and associated protection from colonization
nd infant disease. Additionally, research correlating neonatal col-
nization with antibody levels in breast milk would provide insight
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